Medications for Compulsive Shopping
Primary Recommendation
SSRIs, particularly citalopram, are the recommended first-line pharmacological treatment for compulsive shopping disorder, with doses typically higher than those used for depression (up to 60 mg/day for citalopram). 1
Evidence Base and Treatment Approach
First-Line SSRI Treatment
Citalopram has the strongest evidence for compulsive shopping, with open-label trials showing 71% response rates at mean doses of 35.4 mg/day (range up to 60 mg/day), producing rapid and sustained improvements. 1
Responders achieved "much or very much improved" ratings within 12 weeks, with effects maintained during 6-month follow-up periods when medication was continued. 1
Fluvoxamine showed initial promise in earlier open-label studies but failed to demonstrate efficacy over placebo in controlled trials, making it a less reliable option. 2
Escitalopram demonstrated effectiveness in open-label trials but did not maintain superiority in double-blind phases, suggesting limited utility. 2
Dosing Strategy
Start citalopram at 20 mg/day and increase by 20 mg every 2 weeks (absent marked response or limiting side effects) up to 60 mg/day. 1
Higher doses are typically required for impulse control disorders compared to depression treatment, similar to the dosing pattern seen in OCD. 1
Allow at least 8-12 weeks to assess full therapeutic response before declaring treatment failure. 3
Treatment Duration
Continue treatment for minimum 12-24 months after achieving remission, as relapse rates are significantly higher in patients who discontinue medication prematurely. 1
Patients continuing citalopram during follow-up were substantially less likely to relapse than those who discontinued. 1
Alternative and Augmentation Strategies
When SSRIs Fail
Memantine (an NMDA receptor antagonist) showed effectiveness in pilot open-label studies and may be considered as a second-line agent. 2
Case reports suggest potential benefit from fluoxetine, bupropion, naltrexone (opioid antagonist), and topiramate, though evidence is limited to individual cases without controlled trials. 2
Important Caveat
No placebo-controlled trials have definitively established efficacy for any medication in compulsive shopping disorder. 2 The recommendation for citalopram is based on consistent open-label data with high response rates and sustained benefits, representing the best available evidence despite methodological limitations.
Exclusion Criteria
Screen for and exclude obsessive-compulsive disorder, bipolar disorder, active substance use disorders, and psychotic disorders before initiating SSRI treatment, as these require different treatment approaches. 1
Address comorbid major depression if present, as it is common in impulse control disorders and may influence treatment response. 4
Safety Profile
Citalopram is generally well-tolerated with common side effects including sedation, agitation, gastrointestinal symptoms (especially nausea), headache, and anxiety. 1, 5
Only 3 of 24 patients (12.5%) discontinued due to adverse events in the primary citalopram trial, indicating good overall tolerability. 1
Monitor for QT prolongation with higher doses, particularly in patients with cardiac risk factors or those taking other QT-prolonging medications. 6
Clinical Algorithm
Confirm diagnosis of compulsive shopping (preoccupation with shopping, inability to resist buying unneeded items, marked distress, social/occupational/financial impairment). 1
Exclude psychiatric comorbidities that would alter treatment approach (OCD, bipolar disorder, psychosis, active substance use). 1
Initiate citalopram 20 mg/day, increase by 20 mg every 2 weeks to target dose of 40-60 mg/day as tolerated. 1
Assess response at 8-12 weeks; if inadequate response, ensure dose optimization before switching agents. 3
If citalopram fails, consider trial of memantine or consultation with psychiatry for alternative strategies. 2
Plan for long-term treatment (12-24 months minimum) once remission achieved. 1